<H1>Chapter DOI: 10.1208/aapsj070363<br/>Cited-By Count: 50</H1><table border="1" width="30%"><tr><td>Total References</td><td>73</td></tr><tr><td>Springer references</td><td>7</td></tr><tr><td>Non Springer references</td><td>66</td></tr><tr><td>BibStructured Count</td><td width="10%">69</td></tr><tr><td>BibUnstructured Count</td><td width="10%">4</td></tr><tr><td>DOI already available in SpringerLink</td><td>47</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>12</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>1</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>12</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>13</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience.<Emphasis Type="Italic">Eur J Clin Pharmacol</Emphasis>. 2000;56:1&#8211;18.</td><td><a href=http://dx.doi.org/10.1007/s002280050714>10.1007/s002280050714</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.<Emphasis Type="Italic">Drug Saf</Emphasis>. 2001;24:323&#8211;351.</td><td><a href=http://dx.doi.org/10.2165/00002018-200124050-00001>10.2165/00002018-200124050-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Fenichel RR, Malik M, Antzelevitch C, et al. Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development.<Emphasis Type="Italic">J Cardiovasc Electrophysiol</Emphasis>. 2004;15:475&#8211;495.</td><td><a href=http://dx.doi.org/10.1046/j.1540-8167.2004.03534.x>10.1046/j.1540-8167.2004.03534.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Thomas M, Maconochie JG, Fletcher E. The dilemma of the prolonged QT interval in early drug studies.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 1996;41:77&#8211;81.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2125.1996.tb00163.x>10.1111/j.1365-2125.1996.tb00163.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, ArticleTitle, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Shah RR. Drug-induced QT dispersion: does it predict the risk of torsade de pointes?.<Emphasis Type="Italic">J Electrocardiol</Emphasis>. 2005;38:10&#8211;18.</td><td><a href=http://dx.doi.org/10.1016/j.jelectrocard.2004.09.001>10.1016/j.jelectrocard.2004.09.001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest.<Emphasis Type="Italic">Circulation</Emphasis>. 1991;83:1888&#8211;1894.</td><td><a href=http://dx.doi.org/10.1161/01.CIR.83.6.1888>10.1161/01.CIR.83.6.1888</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, JournalTitle, Year, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR7</td><td>BibArticle</td><td>de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study.<Emphasis Type="Italic">Eur Heart J</Emphasis>. 1999;20:278&#8211;284.</td><td><a href=http://dx.doi.org/10.1053/euhj.1998.1276>10.1053/euhj.1998.1276</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Elming H, Holm E, Jun L, et al. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens.<Emphasis Type="Italic">Eur Heart J</Emphasis>. 1998;19:1391&#8211;1400.</td><td><a href=http://dx.doi.org/10.1053/euhj.1998.1094>10.1053/euhj.1998.1094</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'><span style='background:#BDBAD6'>International Conference on Harmonization (ICH)</span>. The clinical evaluation of QT/QTc interval prolongation and proarrythmic potential for non-atiarrhythmic drugs</span>. Preliminary Concept Paper Draft 4. Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/guidance/6378dft.htm. Accessed June 10, <span style='background:#66FF66'>2004</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Nagy D, DeMeersman R, Gallagher D, et al. QTc interval (cardiac repolarisation): lengthening after meals.<Emphasis Type="Italic">Obes Res</Emphasis>. 1997;5:531&#8211;537.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Stramba-Badiale M, Locati EH, Martinelli A, Courville J, Schwartz PJ. Gender and the relationship between ventricular repolarisation and cardiac cycle length during 24-hour Holter recordings.<Emphasis Type="Italic">Eur Heart J</Emphasis>. 1997;18:1000&#8211;1006.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12</td><td>BibChapter</td><td>Bonate PL. Assessment of QTc interval prolongation in a phase 1 study using Monte Carlo simulation. In: Kimko H, Duffull, S, eds.<Emphasis Type="Italic">Simulation in Clinical Trials</Emphasis>. New York, NY: Marcel Dekker, 2003:353&#8211;367.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Anthony M. Male/female differences in pharmacology: safety issues with QT-prolonging drugs.<Emphasis Type="Italic">J Womens Health</Emphasis>. 2005;14:47&#8211;52.</td><td><a href=http://dx.doi.org/10.1089/jwh.2005.14.47>10.1089/jwh.2005.14.47</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Carella MJ, Mantz SL, Rovner DR, Gossain VV, Bouknight RR, Ferenchick GS. Obesity, adiposity, and lengthening of the QT interval: improvement after loss.<Emphasis Type="Italic">Int J Obes Relat Metab Disord</Emphasis>. 1996;20:938&#8211;942.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15</td><td>BibArticle</td><td>El-Gamal A, Gallagher D, Nawras A, et al. Effects of obesity on QT, RR, and QTc intervals.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 1995;75:956&#8211;959.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(99)80700-0>10.1016/S0002-9149(99)80700-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Franz MR, Swerdlow CD, Liem LB, Schaefer J. Cycle length dependence of human action potential duration in vivo: effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady-state frequencies.<Emphasis Type="Italic">J Clin Invest</Emphasis>. 1988;82:972&#8211;979.</td><td><a href=http://dx.doi.org/10.1172/JCI113706>10.1172/JCI113706</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Lau CP, Freeman AR, Fleming SJ, Malik M, Camm AJ, Ward DE. Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate.<Emphasis Type="Italic">Cardiovasc Res</Emphasis>. 1988;22:67&#8211;72.</td><td><a href=http://dx.doi.org/10.1093/cvr/22.1.67>10.1093/cvr/22.1.67</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation.<Emphasis Type="Italic">J Cardiovasc Electrophysiol</Emphasis>. 2001;12:411&#8211;420.</td><td><a href=http://dx.doi.org/10.1046/j.1540-8167.2001.00411.x>10.1046/j.1540-8167.2001.00411.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 1993;72:17B-22B.</td><td><a href=http://dx.doi.org/10.1016/0002-9149(93)90035-B>10.1016/0002-9149(93)90035-B</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Piotrovsky VK. Population pharmacodynamic and pharmacokinetic modeling via mixed effects.<Emphasis Type="Italic">Curr Opin Drug Discov Devel</Emphasis>. 2000;3:314&#8211;330.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Derendorf H, Lesko LJ, Chaikin P, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2000;40:1399&#8211;1418.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Bazett HC. An analysis of the time relations of electrocardiograms.<Emphasis Type="Italic">Heart</Emphasis>. 1920;7:353&#8211;370.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1111/j.1542-474X.1997.tb00325.x>10.1111/j.1542-474X.1997.tb00325.x</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Fridericia LS. Die systolendauer im elektrokardiogramm bei normalen Menchen und bei Herzkranken.<Emphasis Type="Italic">Acta Med Scand</Emphasis>. 1920;53:469&#8211;486.</td><td><a href=http://dx.doi.org/10.1111/j.0954-6820.1920.tb18266.x>10.1111/j.0954-6820.1920.tb18266.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham heart study).<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 1992;70:797&#8211;801.</td><td><a href=http://dx.doi.org/10.1016/0002-9149(92)90562-D>10.1016/0002-9149(92)90562-D</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Hnatkova K, Malik M. &#8220;Optimum&#8221; formulae for heart rate correction of the QT interval.<Emphasis Type="Italic">Pacing Clin Electrophysiol</Emphasis>. 1999;22:1683&#8211;1687.</td><td><a href=http://dx.doi.org/10.1111/j.1540-8159.1999.tb00390.x>10.1111/j.1540-8159.1999.tb00390.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Batchvarov VN, Ghuran A, Smetana P, et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability.<Emphasis Type="Italic">Am J Physiol Heart Circ Physiol</Emphasis>. 2002;282:H2356-H2363.</td><td><a href=http://dx.doi.org/10.1152/ajpheart.00860.2001>10.1152/ajpheart.00860.2001</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, ArticleTitle, JournalTitle, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Galeazzi RL, Benet LZ, Sheiner LB. Relationship between the pharmacokinetics and pharmacodynamics of procainamide.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1976;20:278&#8211;289.</td><td><a href=http://dx.doi.org/10.1002/cpt1976203278>10.1002/cpt1976203278</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, VolumeID, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Bryson SM, Whiting B, Lawrence JR. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 1978;6:409&#8211;419.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2125.1978.tb04605.x>10.1111/j.1365-2125.1978.tb04605.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_2, Author_FamilyName_1, Year, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Whiting B, Holford NH, Sheiner LB. Quantitative analysis of the disopyramide concentration-effect relationship.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 1980;9:67&#8211;75.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2125.1980.tb04799.x>10.1111/j.1365-2125.1980.tb04799.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, VolumeID, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Desai M, Li L, Desta Z, Malik M, Flockhart D. Variability of heart rate correction methods for the QT interval.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 2003;55:511&#8211;517.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2125.2003.01791.x>10.1046/j.1365-2125.2003.01791.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Piotrovsky</span> <span style='background:#DDDDDD'>VK</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#FFFF80'>Van</span> <span style='background:#BCBCBC'>Peer</span> <span style='background:#DDDDDD'>A.</span></span></aug> <span style='background:#FFD9B3'>Cardiovascular safety data analysis via mixed-effects modelling [Abstract]. Population Approach Group in Europe (PAGE) 9th Meeting, Salamanca</span>, <span style='background:#C0FFC0'>Spain</span>, June <span style='background:#66FF66'>2000</span>. Abstract P8. Available at: <span style='background:#FF3300'>http://www.page-meeting.org/default</span>. <span style='background:#FFFF0F'>asp?id=20&keuze=abstract-view & goto=abstracts & orderby=author & abstract_id=108. Accessed September 30, 2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32</td><td>BibBook</td><td>Beal SL, Sheiner LB.<Emphasis Type="Italic">NONMEM User&#8217;s Guides (I&#8211;VIII)</Emphasis>. San Francisco, CA: UCSF NONMEM Project Group; 1998.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Li L, Desai M, Desta Z, Flockhart D. QT analysis: a complex answer to a simple problem.<Emphasis Type="Italic">Stat Med</Emphasis>. 2004;23:2625&#8211;2643.</td><td><a href=http://dx.doi.org/10.1002/sim.1863>10.1002/sim.1863</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Malik M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes.<Emphasis Type="Italic">Pacing Clin Electrophysiol</Emphasis>. 2002;25:209&#8211;216.</td><td><a href=http://dx.doi.org/10.1046/j.1460-9592.2002.00209.x>10.1046/j.1460-9592.2002.00209.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Malik M, Hnatkova K, Batchvarov V. Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation.<Emphasis Type="Italic">Pacing Clin Electrophysiol</Emphasis>. 2004;27:791&#8211;800.</td><td><a href=http://dx.doi.org/10.1111/j.1540-8159.2004.00530.x>10.1111/j.1540-8159.2004.00530.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Minematsu T, Ohtani H, Sato H, Iga T. Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs.<Emphasis Type="Italic">Biol Pharm Bull</Emphasis>. 1999;22:1341&#8211;1346.</td><td><a href=http://dx.doi.org/10.1248/bpb.22.1341>10.1248/bpb.22.1341</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, VolumeID, FirstPage, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Minematsu T, Ohtani H, Yamada Y, Sawada Y, Sato H, Iga T. Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2001;28:533&#8211;554.</td><td><a href=http://dx.doi.org/10.1023/A:1014460404352>10.1023/A:1014460404352</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Ohtani H, Sato H, Iga T, Kotaki H, Sawada Y. Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats.<Emphasis Type="Italic">Biopharm Drug Dispos</Emphasis>. 1999;20:101&#8211;106.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1099-081X(199903)20:2&lt;101::AID-BDD160&gt;3.0.CO;2-L>10.1002/(SICI)1099-081X(199903)20:2&lt;101::AID-BDD160&gt;3.0.CO;2-L</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Ohtami H, Hanada E, Yamamoto K, Sawada Y, Iga T. Pharmacokinetic-pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats.<Emphasis Type="Italic">Biol Pharm Bull</Emphasis>. 1996;19:1189&#8211;1196.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Hanada E, Ohtami H, Kotaki H, Sawada Y, Sato H, Iga T. Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1999;88:234&#8211;240.</td><td><a href=http://dx.doi.org/10.1021/js980256r>10.1021/js980256r</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Kharidia J, Eddington ND. Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1996;85:595&#8211;599.</td><td><a href=http://dx.doi.org/10.1021/js950473h>10.1021/js950473h</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Thibonnier M, Holford NHG, Upton RA, Blume CD, Williams RL. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1984;12:559&#8211;574.</td><td><a href=http://dx.doi.org/10.1007/BF01059552>10.1007/BF01059552</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Holford NH, Coates PE, Guentert TW, Riegelman S, Sheiner LB. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 1981;11:187&#8211;195.</td><td><a href=http://dx.doi.org/10.1111/j.1365-2125.1981.tb01123.x>10.1111/j.1365-2125.1981.tb01123.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, Year, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Piergies AA, Jr, Ruo TI, Jr, Jansyn EM, Jr, Belknap SM, Jr, Atkinson AJ, Jr. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1987;42:107&#8211;112.</td><td><a href=http://dx.doi.org/10.1038/clpt.1987.117>10.1038/clpt.1987.117</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Lima JJ, Boudoulas H. Stereoselective effects of disopyramide enantiomers in humans.<Emphasis Type="Italic">J Cardiovasc Pharmacol</Emphasis>. 1987;9:594&#8211;600.</td><td><a href=http://dx.doi.org/10.1097/00005344-198705000-00014>10.1097/00005344-198705000-00014</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Karbwang J, Davis TME, Looareesuwan S, Molunto P, Bunnag D, White NJ. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 1993;35:265&#8211;271.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR47</td><td>BibArticle</td><td>Uematsu T, Kanamaru M, Nakashima M. Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers.<Emphasis Type="Italic">J Pharm Pharmacol</Emphasis>. 1994;46:600&#8211;605.</td><td><a href=http://dx.doi.org/10.1111/j.2042-7158.1994.tb03865.x>10.1111/j.2042-7158.1994.tb03865.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, Year, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Shi J, Lasser T, Koziol T, Hinderling PH. Kinetics and dynamics of sematilide.<Emphasis Type="Italic">Ther Drug Monit</Emphasis>. 1995;17:437&#8211;444.</td><td><a href=http://dx.doi.org/10.1097/00007691-199510000-00001>10.1097/00007691-199510000-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Le Coz F, Funck-Brentano C, Morell T, Ghadanfar MM, Jaillon P. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1995;57:533&#8211;542.</td><td><a href=http://dx.doi.org/10.1016/0009-9236(95)90038-1>10.1016/0009-9236(95)90038-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50</td><td>BibArticle</td><td>Saul JP, Ross B, Schaffer MS, et al. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2001;69:145&#8211;157.</td><td><a href=http://dx.doi.org/10.1067/mcp.2001.113795>10.1067/mcp.2001.113795</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51</td><td>BibArticle</td><td>Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2001;28:555&#8211;575.</td><td><a href=http://dx.doi.org/10.1023/A:1014412521191>10.1023/A:1014412521191</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52</td><td>BibArticle</td><td>Phillips L, Grasela TH, Agnew JR, Ludwig EA, Thompson GA. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2001;70:370&#8211;383.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(01)56650-3>10.1016/S0009-9236(01)56650-3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, Year, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR53</td><td>BibArticle</td><td>Corey A, Al-Khalidi H, Brezovic C, et al. Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing.<Emphasis Type="Italic">Biopharm Drug Dispos</Emphasis>. 1999;20:59&#8211;68.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1099-081X(199903)20:2&lt;59::AID-BDD155&gt;3.0.CO;2-6>10.1002/(SICI)1099-081X(199903)20:2&lt;59::AID-BDD155&gt;3.0.CO;2-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54</td><td>BibArticle</td><td>Corey A, Agnew J, Brum J, Parekh N, Valentine S, Williams M. Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 1999;39:1263&#8211;1271.</td><td><a href=http://dx.doi.org/10.1177/00912709922012079>10.1177/00912709922012079</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Brynne L, McNay JL, Schaefer HG, Swedberg K, Wiltse CG, Karlsson MO. Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.<Emphasis Type="Italic">Br J Clin Pharmacol</Emphasis>. 2001;51:35&#8211;43.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2125.2001.01320.x>10.1046/j.1365-2125.2001.01320.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Seyfert H, Wendt T. Circadian rhythm of QT- and QTc-intervals in diabetics and hypertensives.<Emphasis Type="Italic">Z Kardiol</Emphasis>. 2003;92:384&#8211;386.</td><td><a href=http://dx.doi.org/10.1007/s00392-003-0936-1>10.1007/s00392-003-0936-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Bonnemeier H, Wiegand UKH, Braasch W, Brandes A, Richardt G, Potratz J. Circadian profile of QT interval and QT interval variability in 172 healthy volunteers.<Emphasis Type="Italic">Pacing Clin Electrophysiol</Emphasis>. 2003;26:377&#8211;382.</td><td><a href=http://dx.doi.org/10.1046/j.1460-9592.2003.00053.x>10.1046/j.1460-9592.2003.00053.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>Yeragani VK, Pohl R, Jampala VC, Balon R, Kay J, Igel G. Effect of posture and isoproterenol on beat-to-beat heart rate and QT variability.<Emphasis Type="Italic">Neuropsychobiology</Emphasis>. 2000;41:113&#8211;123.</td><td><a href=http://dx.doi.org/10.1159/000026642>10.1159/000026642</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Yeragani VK, Pohl R, Balon R, Jampala VC, Jayaraman A. Twentyfour-hour QT interval variability: increased QT variability during sleep in patients with panic disorder.<Emphasis Type="Italic">Neuropsychobiology</Emphasis>. 2002;46:1&#8211;6.</td><td><a href=http://dx.doi.org/10.1159/000063568>10.1159/000063568</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Ong JJ, Sarma JS, Venkataraman K, Levin SR, Singh BN. Circadian rhythmicity of heart rate and QTc interval in diabetic autonomic neuropathy: implications for the mechanism of sudden death.<Emphasis Type="Italic">Am Heart J</Emphasis>. 1993;125:744&#8211;752.</td><td><a href=http://dx.doi.org/10.1016/0002-8703(93)90166-7>10.1016/0002-8703(93)90166-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Koch HJ, Raschka C, Banzer W. Diurnal variation of ECG intervals and R or T amplitudes in healthy malesubjects assessed by means of spectral and cosinor analysis.<Emphasis Type="Italic">Jpn Heart J</Emphasis>. 1999;40:45&#8211;53.</td><td><a href=http://dx.doi.org/10.1536/jhj.40.45>10.1536/jhj.40.45</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62</td><td>BibArticle</td><td>Morganroth J, Brown AM, Critz S, et al. Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 1993;72:26B-31B.</td><td><a href=http://dx.doi.org/10.1016/0002-9149(93)90037-D>10.1016/0002-9149(93)90037-D</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63</td><td>BibArticle</td><td>Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events.<Emphasis Type="Italic">J Am Coll Cardiol</Emphasis>. 1996;27:76&#8211;83.</td><td><a href=http://dx.doi.org/10.1016/0735-1097(95)00426-2>10.1016/0735-1097(95)00426-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Neyroud N, Maison-Blanche P, Denjoy I, et al. Diagnostic performance of QT interval variables from 24-h electrocardiography in the long QT syndrome.<Emphasis Type="Italic">Eur Heart J</Emphasis>. 1998;19:158&#8211;165.</td><td><a href=http://dx.doi.org/10.1053/euhj.1997.0730>10.1053/euhj.1997.0730</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Gang Y, Guo X-H, Reardon M, Hnatkova K, Camm AJ, Malik M. Circadian variation of the QT interval in patients with sudden cardiac death after myocardial infarction.<Emphasis Type="Italic">Am J Cardiol</Emphasis>. 1998;81:950&#8211;956.</td><td><a href=http://dx.doi.org/10.1016/S0002-9149(98)00071-X>10.1016/S0002-9149(98)00071-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Smetana P, Batchvarov V, Hnatkova K, Camm AJ, Malik M. Circadian rhythm of the corrected QT interval: impact of different heart rate correction models.<Emphasis Type="Italic">Pacing Clin Electrophysiol</Emphasis>. 2003;26:383&#8211;386.</td><td><a href=http://dx.doi.org/10.1046/j.1460-9592.2003.00054.x>10.1046/j.1460-9592.2003.00054.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67</td><td>BibArticle</td><td>Nelson W, Tong YL, Lee JK, Halberg F. Methods for cosinorrhythmometry.<Emphasis Type="Italic">Chronobiologia</Emphasis>. 1979;6:305&#8211;323.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR68</td><td>BibChapter</td><td>De Prins J, Hequet B. Data processing in chronobiological studies. In: Touiton Y, Haus E, eds.<Emphasis Type="Italic">Biologic Rhythms in Clinical and Laboratory Medicine</Emphasis>. Berlin, Germany, Springer Verlag; 1992:90&#8211;112.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-3-642-78734-8>10.1007/978-3-642-78734-8</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle, Year</td><td>CrossRef</td></tr><tr><td>CR69</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Piotrovsky</span> <span style='background:#DDDDDD'>VK</span></span></aug>. <span style='background:#FFD9B3'>Population PK-PD analysis of cardiovascular effects of non-cardiovascular drugs with the emphasis on QT prolongation. Population Approach Group in Europe (PAGE) 12th Meeting, Verona</span>, <span style='background:#C0FFC0'>Italy</span>, June <span style='background:#66FF66'>2003</span>. Available at: <span style='background:#FF3300'>http://www.page-meeting</span>. <span style='background:#FFFF0F'>org/default.asp?id=23&keuze=abstract-view & goto=abstracts & orderby=author & abstract_id=427. Accessed September 30, 2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR70</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Wade</span> <span style='background:#DDDDDD'>JR</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Karlsson</span> <span style='background:#DDDDDD'>MO.</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Combining</span> <span style='background:#DDDDDD'>PK</span></span></aug> <span style='background:#FFD9B3'>and PD data during population PK/PD analysis [Abstract]. Population Approach Group in Europe (PAGE) 8th Meeting, Saintes</span>, <span style='background:#C0FFC0'>France</span>, June <span style='background:#66FF66'>1999</span>. Available at: <span style='background:#FF3300'>http://www.page-meeting.org/default.asp?id=19&keuze=abstract-view&goto=abstracts&orderby=author&abstract_id=139</span>. <span style='background:#FFFF0F'>Accessed September 30, 2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Morganroth J. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment.<Emphasis Type="Italic">J Electrocardiol</Emphasis>. 2004;37:25&#8211;29.</td><td><a href=http://dx.doi.org/10.1016/j.jelectrocard.2003.11.004>10.1016/j.jelectrocard.2003.11.004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Bonate PL, Russell T. Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 1999;39:349&#8211;358.</td><td><a href=http://dx.doi.org/10.1177/00912709922007912>10.1177/00912709922007912</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73</td><td>BibArticle</td><td>Bonate PL. Rank power of metrics used to assess QTc interval prolongation by clinical trial simulation.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2000;40:468&#8211;474.</td><td><a href=http://dx.doi.org/10.1177/00912700022009233>10.1177/00912700022009233</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>